Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

12 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Recomputed 1 test: 1 consistent, 0 inconsistent, 1 via agent-written checks.

1 integrity concern flagged (0 high).

9 copyedit issues flagged (1 major): mostly consistency, clarity, grammar.

Checked 29 references: 29 verified.

1 data/code link checked; 1 live.

In this post-publication audit, the paper has a core numerical inconsistency (1,802 vs. 1,602) that an informed reader should weigh as a potential data-entry error, and lacks a data availability statement and participant sex reporting. These issues warrant an erratum or correction; independent re-analysis would also be prudent to confirm that the inconsistency does not propagate to other results.

1. 1.
   HIGHstatistics

   Correct the numerical inconsistency in Results, Efficacy Analyses: change '1,802' to '1,602' to match the total patients with follow-up data.

   This demonstrable error (confirmed by copyedit and integrity checks) undermines reader trust in the reported analyses and must be addressed in a correction.
2. 2.
   HIGHdata code

   Add a data availability statement specifying how de-identified individual patient data can be accessed (e.g., via the NCTN/NCORP Data Archive or YODA project), with conditions and a DOI if applicable.

   Current manuscript lacks any data access information, which is expected for clinical trials and is a common journal requirement.
3. 3.
   HIGHreporting

   Report the sex of participants explicitly in Table 1 (e.g., 'All patients were female' or include a sex row).

   Sex is a critical biological variable in breast cancer; its absence is a notable gap that limits generalizability assessment.
4. 4.
   HIGHreporting

   Add a statement of compliance with the Declaration of Helsinki or ICH-GCP in the Methods section.

   Regulatory compliance is a standard expectation for human-subject research; its absence is a minor but fixable gap.
5. 5.
   HIGHrigor

   Identify the manufacturer and model of the radiation therapy equipment (linear accelerator) and treatment planning software (name and version) in the Radiation Therapy Regimens section.

   Replication of the intervention requires specifying equipment; this is an investigational resource in a device/radiotherapy trial.
6. 6.
   HIGHstatistics

   Specify the statistical software (e.g., SAS version 9.4, R version 4.x) used for all analyses in the Statistical Analysis section.

   Software identification is needed for reproducibility and is a standard reporting expectation.
7. 7.
   MEDIUMreporting

   Describe the randomization method (e.g., centralized permuted-block randomization) and allocation concealment in the Methods.

   CONSORT requires explicit randomization method description; current text only says 'randomly assigned.'
8. 8.
   MEDIUMreporting

   Acknowledge the open-label design and provide a brief rationale (e.g., 'Sham radiation was not feasible or ethical').

   Even when blinding is impossible, stating its absence and rationale is expected for trial transparency.
9. 9.
   MEDIUMreporting

   Report weight and health status (e.g., ECOG performance status) of participants in baseline characteristics.

   These factors affect treatment tolerance and outcome generalizability; age alone is insufficient.
10. 10.
    MEDIUMreporting

    Mention adherence to CONSORT 2010 reporting guidelines in the Methods and confirm a flow diagram was included.

    Many journals require explicit reporting guideline adherence for clinical trials.
11. 11.
    MEDIUMstatistics

    Provide exact p-values for all secondary endpoints (locoregional recurrence-free interval, distant recurrence-free interval, disease-free survival, overall survival) in the results text or tables.

    Only the primary endpoint's exact p-value is given; secondary endpoints should be fully transparent.
12. 12.
    LOWcopyedit

    Fix the incomplete placeholder '( in the )' in Methods, Trial Design and Eligibility — replace with a proper reference to the Supplementary Appendix figure.

    This is a broken cross-reference that would confuse readers.
13. 13.
    LOWcopyedit

    Remove the redundant conjunction in 'they vouch' — rephrase to 'the authors had full access to the data, analyzed them, and vouch for the accuracy...' in Methods.

    Improves readability and removes a grammatical inconsistency.
14. 14.
    LOWrigor

    Either provide supporting data from this trial for the claim that results are 'equally applicable to moderately hypofractionated radiation therapy' (Discussion) or remove the claim.

    The claim_audit flagged this as unsupported; the trial used conventional fractionation and only cites an external reference.